April 02, 2026 07:00 ET  | Source: Adagene Inc. Dose-Dependent Efficacy Results: As of the latest data cut, muzastotug achieved a 31% (8/26) confirmed overall response rate (ORR) in the combined 20 mg/kg dose cohorts, showing a clear improvement over the 13% ORR (5/39) in the combined 10 mg/kg dose cohorts Extended Durability: Median duration of response (mDOR) […]

April 01, 2026 17:00 ET  | Source: Adagene Inc. In 2025, muzastotug showed 29% confirmed overall response rate (ORR) among 21 patients with MSS CRC in the 20 mg/kg dose cohorts Median overall survival (OS) for the 10 mg/kg cohorts was 19.4 months, with a median follow-up of 17.8 months  4% overall discontinuation rate, no dose limiting toxicities,

April 01, 2026 06:00 ET  | Source: Zymeworks Inc. VANCOUVER, British Columbia, April 01, 2026 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the appointment of Ms. Kristin Stafford as Chief Financial Officer, effective April 1, 2026.

April 01, 2026 02:40 ET  | Source: AskBio Inc. (AskBio) Durham, N.C., April 01, 2026 (GLOBE NEWSWIRE) — AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that the randomization of the last participant was completed earlier this year for GenePHIT, its Phase 2 clinical trial

March 31, 2026 02:45 ET  | Source: Standing Ovation PRESS RELEASE Standing Ovation raises $34.2 million to scale up its breakthrough technology for producing dairy proteins through precision fermentation, offering a sovereign and sustainable response to the surge in global demand for protein Paris, 31 March 2026 – Standing Ovation, a French precision fermentation pioneer producing next-generation proteins,

March 30, 2026 08:00 ET  | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel and PARSIPPANY, N.J., March 30, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced three milestones in its biosimilar portfolio, demonstrating continued momentum in the advancement of its Pivot to Growth strategy. The United States (U.S.) Food and

March 30, 2026 06:00 ET  | Source: Zymeworks Inc. VANCOUVER, British Columbia, March 30, 2026 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to

Indira IVF and Abu Ghosh Fertility Group join the Nucleus IVF+ Network, as families seek a more complete picture of their future child’s health.  March 26, 2026 10:05 ET  | Source: Nucleus Genomics Inc. NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) — Nucleus Genomics today announced joint ventures with Indira IVF, India’s largest IVF service provider, and Abu Ghosh Fertility

March 26, 2026 09:10 ET  | Source: Royal Philips March 26, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for EchoNavigator R5.0 with DeviceGuide, an AI-powered software solution that assists physicians during one of interventional cardiology’s most

March 25, 2026 12:15 ET  | Source: Io Therapeutics, Inc. SPRING, Texas, March 25, 2026 (GLOBE NEWSWIRE) — Io Therapeutics, Inc., a privately held pharmaceutical company headquartered in Spring, Texas; announced today publication online in Scientific Reports – Nature, of collaborative studies with Duke University scientists on effects of the company’s anti-cancer compound IRX4204, on human multiple myeloma,

March 25, 2026 05:00 ET  | Source: Royal Philips March 25, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has announced the launch of its intuitive interventional guidance platform, IntraSight Plus, which is cleared for clinical use in the USA and Europe. With CE marking and FDA 510(k) clearance, the

March 25, 2026 02:36 ET  | Source: Boehringer Ingelheim Limited Intended audience: global business, financial and trade media Ingelheim, March 25, 2026 – Boehringer Ingelheim successfully delivered on key launches in its Human Pharma business in 2025, bringing two medicines with FDA Breakthrough Therapy designation for lung cancer and pulmonary fibrosis to market in the second half

March 24, 2026 09:03 ET  | Source: SK pharmteco Inc. RANCHO CORDOVA, Calif., March 24, 2026 (GLOBE NEWSWIRE) — SK pharmteco, a leading global contract development and manufacturing organization (CDMO), and Prozomix, a pioneer in enzyme discovery and diversity, today announced a strategic partnership. This collaboration aims to integrate Prozomix’s extensive biocatalyst libraries into SK pharmteco’s small-molecule development and

March 24, 2026 04:30 ET  | Source: Royal Philips March 24, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it ranked No. 1 among medical technology companies in the European Patent Office’s (EPO) Technology Dashboard 2025. Medical technology is the most important domain for Dutch patent applications at the

March 24, 2026 02:00 ET  | Source: Sanofi Winthrop Industrie Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid Paris and Tarrytown, NY, March 24, 2026. The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of adults